MWM
CPRX

Moran Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Moran Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.69M Buy
180,915
+11,954
+7% +$353K 0.16% 197
2026
Q1 		$4.18M Buy
168,961
+137,791
+442% +$3.28M 0.13% 218
2025
Q4 		$728K Buy
31,170
+4,998
+19% +$111K 0.02% 374
2025
Q3 		$516K Sell
26,172
-7,263
-22% -$149K 0.02% 403
2025
Q2 		$726K Buy
33,435
+2,225
+7% +$52.5K 0.02% 355
2025
Q1 		$757K Buy
31,210
+21,135
+210% +$476K 0.03% 329
2024
Q4 		$210K Buy
+10,075
New +$216K 0.01% 402

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Moran Wealth Management's CPRX Position: Q2 2026 in Review

Moran Wealth Management increased its Catalyst Pharmaceutical (CPRX) stake by 7.1% in Q2 2026, buying an estimated $353K and bringing the position to 180,915 shares worth $5.69M. The position accounts for 0.16% of the portfolio, ranked #197.

Moran Wealth Management first reported a position in CPRX in Q4 2024 and has held it in 7 quarters since. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Moran Wealth Management held 180,915 shares of Catalyst Pharmaceutical worth $5.69M as of Q2 2026.
  • Moran Wealth Management bought 11,954 Catalyst Pharmaceutical shares in Q2 2026, an estimated $353K.
  • Catalyst Pharmaceutical made up 0.16% of Moran Wealth Management's portfolio in Q2 2026, its #197 holding.
  • Moran Wealth Management first reported a position in Catalyst Pharmaceutical in Q4 2024 and has held it in 7 quarters since.
  • 395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Moran Wealth Management's 13F filing for Q2 2026, filed 5 Aug 2026.